DEALS: Novartis expands OTC operations


Novartis wins big OTC deal.


DEALS

WHO

WITH

WHAT

SCOOP

Novartis

Bristol-Myers Squibb

$660 million acquisition of US and Canadian OTC division

Novartis gains rights to a broad range of OTC drugs, including Excedrin and Comtrex.

Omnicare

excelleRx

$269 million buyout

Omnicare gains a provider of comprehensive pharmaceutical care services, primarily for hospice patients.

McKesson

D&K Healthcare Resources

$207 million buyout

McKesson adds a regional drug distributor to its operations.

Sosei

Arakis

$187.4 million buyout

The deal expands Sosei's pipeline with several compounds in development, including a $375 million global partnership with Novartis for its lead product AD 237.

Aptuit

Quintiles Transnational

$125 million business unit acquisition

The units will be reorganized by Aptuit into three global business lines: Preclinical Technologies, Pharmaceutical Sciences and Packaging & Logistics.

Roche Group

GlycArt Biotechnology

Buyout

Roche gains new technology technology for enhancing the efficacy of antibodies.

American Pacific

Aerojet Fine Chemicals

Buyout for $119 million plus liabilities

American Pacific buys an established player in the sale of active pharmaceutical ingredients.

Assay Designs

Stressgen Bioreagents

Acquisition

Stressgen develops and markets antibodies, proteins and related kits to life sciences researchers worldwide.

Hi-Tech Pharmacal

Rodlen Laboratories

$4.4 million brand buyout

Hi-Tech gains control of Zostrix OTC analgesic creams.

Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.